Dubermatinib
- Generic Name
- Dubermatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O2S
- CAS Number
- 1341200-45-0
- Unique Ingredient Identifier
- 14D65TV20J
- Background
Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
- Associated Conditions
- -
- Associated Therapies
- -
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 3
- Registration Number
- NCT04518345
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath